Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users

Rheumatology International

Volumn 37, Issue 6, 2017, Pages 897-904

  Wabe, Nasir ^a   Lee, Anita ^b   Wechalekar, Mihir ^c   McWilliams, Leah ^b   Proudman, Susanna ^b   Wiese, Michael ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

Clinical outcomes; Medication adherence; Propensity scores; Rheumatoid arthritis; Treatment outcomes

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONFOUNDING VARIABLE; DAS28; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; COMBINATION DRUG THERAPY; CONVALESCENCE; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; REMISSION; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; LONGITUDINAL STUDIES; MEDICATION ADHERENCE; MIDDLE AGED; RECOVERY OF FUNCTION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85011695946     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-017-3655-z     Document Type: Article

References (29)

1. Wabe N, Wiese MD (2016) Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. J Eval Clin Pract. doi:10.1111/jep.12620 (Epub ahead of print)
2. Salt E, Frazier SK (2010) Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs 29:260–275
3. Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33:901–913
4. Tamás K (2010) Clinical and pharmacoeconomic impact of patient medication adherence. Dissertation, Semmelweis University
5. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW (2002) Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 40:794–811
6. Cannon GW, Mikuls TR, Hayden CL et al (2011) Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 63:1680–1690
7. Pasma A, Schenk CV, Timman R et al (2015) Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Res Ther 17:281
8. Bluett J, Morgan C, Thurston L et al (2015) Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in rheumatoid arthritis genetics and genomics study syndicate cohort. Rheumatology (Oxford) 54:494–499
9. Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637
10. Wabe N, Sorich M, Wechalekar M et al (2015) Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Res Ther 17:48
11. Wabe N, Sorich MJ, Wechalekar MD et al (2016) Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term? Int J Clin Pract 70:340–350
12. Wabe N, Sorich MJ, Wechalekar MD et al (2015) Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. Int J Rheum Dis. doi:10.1111/1756-185X.12816 (Epub ahead of print)
13. Proudman SM, Keen HI, Stamp LK et al (2007) Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 37:99–111
14. Pincus T, Summey JA, Soraci SA Jr et al (1983) Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346–1353
15. DeVellis RF, Callahan LF (1993) A brief measure of helplessness in rheumatic disease: the helplessness subscale of the Rheumatology Attitudes Index. J Rheumatol 20:866–869
16. Wells G, Becker JC, Teng J et al (2009) Validation of the 28-joint disease activity score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68:954–960
17. Smolen J, Breedveld F, Schiff M et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257
18. Choudhry NK, Shrank WH, Levin RL et al (2009) Measuring concurrent adherence to multiple related medications. Am J Manag Care 15:457–464
19. Van Gestel A, Prevoo M, Van’t Hof M et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 39:34–40
20. Kosinski M, Zhao SZ, Dedhiya S et al (2000) Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 43:1478–1487
21. Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46: 399–424
22. Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34:3661–3679
23. Wabe NT, Sorich MJ, Wechalekar MD et al (2016) Effect of adherence to protocolized targeted intensifications of disease-modifying antirheumatic drugs on treatment outcomes in rheumatoid arthritis: results from an australian early arthritis cohort. J Rheumatol 43:1643–1649
24. Barnabe C, Sun Y, Boire G et al (2015) Heterogeneous disease trajectories explain variable radiographic, function and quality of life outcomes in the Canadian early arthritis cohort (CATCH). PloS one 10:e0135327
25. Siemons L, Ten Klooster PM, Vonkeman HE et al (2014) Distinct trajectories of disease activity over the first year in early rheumatoid arthritis patients following a treat-to-target strategy. Arthritis Care Res (Hoboken) 66:625–630
26. Quinn MA, Emery P (2003) Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 21:S154–S157
27. Jimmy B, Jose J (2011) Patient medication adherence: measures in daily practice. Oman Med J 26:155–159
28. McCaffrey DF, Griffin BA, Almirall D et al (2013) A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 32:3388–3414
29. Yu AP, Yu YF, Nichol MB (2010) Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes—an application of marginal structural models. Value Health 13:1038–1045